• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Onco360 Chosen as a Specialty Pharmacy Provider for Besremi

News
Article

Besremi was approved recently to treat a rare blood disease.

PharmaEssentia has chosen Onco360 to be a specialty pharmacy partner for Besremi (ropeginterferon alfa-2b-njft). The FDA recently approved the therapy as a treatment for adult patients with polycythemia vera. This is the first interferon approved to treat a disease that causes the overproduction of red blood cells.

Related: FDA Approves Treatment for Rare Blood Disease

“We are committed to supporting the highly specialized needs of polycythemia vera patients and their physicians across the United States,” Benito Fernandez, chief commercial officer, Onco360, said in a statement.

Polycythemia vera results from abnormal red blood cell proliferation due to genetic mutations involving the Janus Kinase 2 (JAK2) gene. Due to over-production of red blood cells, patients with polycythemia vera have blood which is thicker than normal, potentially resulting in increased risks for thrombosis and reduction in blood flow.

Besremi is a long-acting drug that patients take by injection under the skin once every two weeks.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.